Press Releases

Date	Title
February 1, 2019	Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement CRANBURY, N.J. , Feb. 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the final tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business
January 22, 2019	Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants CRANBURY, N.J. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK, OTLKW) (the “Company”) today announced that its publicly traded Series A warrants (Nasdaq: OTLKW) have been amended to lower the exercise price to $1.50 per share and further extend the maturity until 5:00
January 2, 2019	Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement CRANBURY, N.J. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the third tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business
December 18, 2018	Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018 CRANBURY, N.J., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK ) (the “Company”) today reported financial results and business highlights for its fiscal year ended September 30, 2018. Recent Highlights: Initiated ONS-5010 clinical study in wet AMD with first patient
December 3, 2018	Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps in Executing ONS-5010 Clinical and Regulatory Strategy Company changes name to Outlook Therapeutics, Inc. ; ticker symbol to “OTLK” Jeff Evanson joins team as Chief Commercial Officer Terry Dagnon joins team as Chief Operating Officer Closed second tranche of private placement for additional $4.0 million from BioLexis CRANBURY, N.J. , Dec.
November 6, 2018	Oncobiologics Advances ONS-5010 into wet AMD Clinical Trial Receives commitment for $20 million in proceeds from equity private placement Restructures and extends maturity on $13.5 million of outstanding senior secured notes CRANBURY, N.J. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it has begun dosing patients
August 14, 2018	Oncobiologics Provides Business Update and Reports Third Quarter Financial Results for Fiscal 2018 CRANBURY, N.J. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ: ONS) today reported financial results and business highlights for its three and nine months ended June 30, 2018 . Recent Highlights: Continued to prepare ONS-5010 for clinical trials Converted majority of Series A
August 2, 2018	Oncobiologics Appoints Lawrence A. Kenyon as President and CEO CRANBURY, N.J. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that Lawrence A. Kenyon , its Chief Financial Officer (CFO) and Corporate Secretary, has been appointed to the role of President and Chief Executive Officer (CEO), and has joined the Company’s Board
July 19, 2018	Oncobiologics Completes Exchange of Series A Convertible Preferred Stock for Newly Created Series A-1 Convertible Preferred Stock CRANBURY, N.J. , July 19, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) today announced that, on July 18, 2018 , the Company completed the exchange of an aggregate of 58,735 shares of voting Series A Convertible Preferred Stock (the “Series A”) held by GMS Tenshi Holdings Pte.
July 11, 2018	Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements CRANBURY, N.J. , July 11, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (Nasdaq:ONS) today announced that, on July 10, 2018 , the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with the applicable requirements for the continued listing of